KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

Researchers have unlocked a powerful new way to fight solid tumors using smart immune cells that stay active longer and hit ...

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric ...

Researchers have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating ...

Iovance's Amtagvi is the first TIL therapy approved by the U.S. Food and Drug Administration (FDA). Its first approved ...

Scientists are looking for answers about how these confounding trips, known as metastases, occur throughout the human body ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Researchers have explored the evolution of the genetic change that causes chronic myeloid leukaemia and show its ability to drive the disease.